Cardlytics (NASDAQ:CDLX) issued its earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.31, Morningstar.com reports. Cardlytics had a negative return on equity of 92.07% and a negative net margin of 35.20%. The firm had revenue of $35.99 million for the quarter, compared to analysts’ expectations of $36.11 million. During the same quarter last year, the business earned ($0.35) earnings per share. The company’s revenue was up 10.0% compared to the same quarter last year.

Shares of NASDAQ CDLX traded up $4.38 during mid-day trading on Friday, reaching $21.25. 1,503,163 shares of the company’s stock were exchanged, compared to its average volume of 197,851. The firm has a market cap of $382.90 million, a P/E ratio of -9.93 and a beta of 3.36. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.40 and a quick ratio of 2.40. Cardlytics has a twelve month low of $9.80 and a twelve month high of $28.29.

A number of equities analysts have issued reports on CDLX shares. Bank of America upgraded Cardlytics from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Tuesday, January 15th. SunTrust Banks restated a “buy” rating and set a $25.00 target price on shares of Cardlytics in a report on Wednesday, March 6th. ValuEngine cut Cardlytics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 23rd. Zacks Investment Research upgraded Cardlytics from a “sell” rating to a “hold” rating in a report on Thursday, March 14th. Finally, KeyCorp raised their target price on Cardlytics from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Friday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.57.

In related news, CFO David Thomas Evans sold 2,505 shares of Cardlytics stock in a transaction that occurred on Friday, March 29th. The stock was sold at an average price of $16.21, for a total value of $40,606.05. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Kirk Somers sold 2,591 shares of Cardlytics stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $15.67, for a total value of $40,600.97. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,087 shares of company stock worth $348,050.

A number of institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC raised its position in Cardlytics by 2.3% in the 1st quarter. SG Americas Securities LLC now owns 61,277 shares of the company’s stock valued at $1,014,000 after buying an additional 1,402 shares during the last quarter. BlackRock Inc. raised its position in Cardlytics by 0.4% in the 4th quarter. BlackRock Inc. now owns 422,718 shares of the company’s stock valued at $4,578,000 after buying an additional 1,610 shares during the last quarter. CIBC Private Wealth Group LLC raised its position in Cardlytics by 6.7% in the 1st quarter. CIBC Private Wealth Group LLC now owns 37,745 shares of the company’s stock valued at $624,000 after buying an additional 2,375 shares during the last quarter. Bank of America Corp DE raised its position in Cardlytics by 0.9% in the 4th quarter. Bank of America Corp DE now owns 270,025 shares of the company’s stock valued at $2,924,000 after buying an additional 2,471 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in Cardlytics by 72.4% in the 3rd quarter. Wells Fargo & Company MN now owns 8,004 shares of the company’s stock valued at $201,000 after buying an additional 3,361 shares during the last quarter. 80.90% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/cardlytics-cdlx-issues-earnings-results/3005365.html.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Read More: Investing in Blue-Chip Stocks

Earnings History for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.